Loncastuximab Tesirine for Marginal Zone Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a medication called loncastuximab tesirine in patients with immune cell cancers. The medication works by finding and sticking to cancer cells, then releasing a poison to kill them. Researchers want to see if this treatment is effective and safe for these patients. Loncastuximab tesirine is a recently approved treatment for a type of immune cell cancer that has returned or not responded to previous treatments.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently receiving anticancer therapy or have taken certain anticancer medications or investigational drugs within specific time frames before the trial starts. It's best to discuss your current medications with the trial team.
Is Loncastuximab Tesirine safe for humans?
Loncastuximab Tesirine, also known as Zynlonta, has been shown to have a tolerable safety profile in clinical trials for diffuse large B-cell lymphoma, with common side effects including low white blood cell counts, low platelet counts, and elevated liver enzymes. It has been safely used even in patients with severe liver issues, but always consult with a healthcare provider for personal medical advice.12345
What makes the drug Loncastuximab Tesirine unique for treating marginal zone lymphoma?
What data supports the effectiveness of the drug Loncastuximab Tesirine for treating Marginal Zone Lymphoma?
Loncastuximab Tesirine has shown effectiveness in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a response rate of about 48% in clinical trials. While it is not specifically approved for Marginal Zone Lymphoma, its success in similar B-cell lymphomas suggests potential effectiveness.123411
Who Is on the Research Team?
Izidore Lossos, MD
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
This trial is for adults over 18 with Marginal Zone Lymphoma who've had at least one prior systemic therapy including an anti-CD20 antibody. They should have measurable disease or specific criteria met for non-measurable disease, and be able to undergo biopsies if needed. Key exclusions include recent cancer treatments, other malignancies within the last 3 years, certain heart conditions, liver cirrhosis, autoimmune disorders requiring strong immunosuppression, active infections or HIV/HBV/HCV infection.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Loncastuximab Tesirine
Loncastuximab Tesirine is already approved in United States, European Union for the following indications:
- Diffuse large B-cell lymphoma (DLBCL)
- DLBCL arising from low-grade lymphoma
- High-grade B-cell lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- DLBCL arising from low-grade lymphoma
- High-grade B-cell lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
ADC Therapeutics S.A.
Industry Sponsor